Cover Image
Market Research Report
Product code 
1046764

North America Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

Published: | KBV Research | 71 Pages | Delivery time: 1-2 business days

Price

Back to Top
North America Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027
Published: November 30, 2021
KBV Research
Content info: 71 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The North America Filgrastim Market would witness market growth of 7.3% CAGR during the forecast period (2021-2027).

Filgrastim is majorly given for neutropenia that is caused by bone marrow transplantation and chemotherapy in patients. It is one of the supportive therapies used in numerous kinds of cancers. In the past few years, cancer prophylaxis has significantly increased in various developed nations and many governments have taken supportive initiatives for creating awareness and educating people about its early treatment. Thus, such aspects are estimated to propel the growth of the filgrastim market over the forecast period.

Approved biosimilars like Neukine, Colstim, Grafeel, and Filcad that are comparatively inexpensive and widely available in emerging nations, thereby augment the growth of the filgrastim market during the forecast period.

The strong healthcare system of various developed nations of this region including the US and Canada is estimated to fuel the growth of the regional filgrastim market over the forecast period. Factors like the increasing prevalence of chronic diseases and the growing geriatric populations are anticipated to augment the growth of the regional filgrastim market in the coming years.

The presence of various key market players in this region along with the increasing investment in R&D activities to develop more effective products would accelerate the growth of the regional market. In addition, supportive reimbursement policies of the governments in this region, are motivating patients to get their treatment and thus, opening the growth avenues for the players operating in the regional market.

The US market dominated the North America Filgrastim Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $266.7 million by 2027. The Canada market is poised to grow at a CAGR of 9.7% during (2021 - 2027). Additionally, The Mexico market is would showcase a CAGR of 8.7% during (2021 - 2027).

Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksoz Group

Scope of the Study

Market Segments covered in the Report:

By Drug Type

  • Biosimilar and
  • Biologic

By Indication

  • Chemotherapy induced Neutropenia
  • Chronic Neutropenia and
  • Other Indications

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies and
  • Online Pharmacies

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled

  • Abbott Laboratories
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Apotex, Inc.
  • Toksoz Group

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 North America Filgrastim Market, by Drug Type
    • 1.4.2 North America Filgrastim Market, by Indication
    • 1.4.3 North America Filgrastim Market, by Distribution Channel
    • 1.4.4 North America Filgrastim Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. North America Filgrastim Market by Drug Type

  • 3.1 North America Biosimilar Market by Country
  • 3.2 North America Biologic Market by Country

Chapter 4. North America Filgrastim Market by Indication

  • 4.1 North America Chemotherapy induced Neutropenia Market by Country
  • 4.2 North America Chronic Neutropenia Market by Country
  • 4.3 North America Other Indications Market by Country

Chapter 5. North America Filgrastim Market by Distribution Channel

  • 5.1 North America Hospital Pharmacies Market by Country
  • 5.2 North America Retail Pharmacies Market by Country
  • 5.3 North America Online Pharmacies Market by Country

Chapter 6. North America Filgrastim Market by Country

  • 6.1 US Filgrastim Market
    • 6.1.1 US Filgrastim Market by Drug Type
    • 6.1.2 US Filgrastim Market by Indication
    • 6.1.3 US Filgrastim Market by Distribution Channel
  • 6.2 Canada Filgrastim Market
    • 6.2.1 Canada Filgrastim Market by Drug Type
    • 6.2.2 Canada Filgrastim Market by Indication
    • 6.2.3 Canada Filgrastim Market by Distribution Channel
  • 6.3 Mexico Filgrastim Market
    • 6.3.1 Mexico Filgrastim Market by Drug Type
    • 6.3.2 Mexico Filgrastim Market by Indication
    • 6.3.3 Mexico Filgrastim Market by Distribution Channel
  • 6.4 Rest of North America Filgrastim Market
    • 6.4.1 Rest of North America Filgrastim Market by Drug Type
    • 6.4.2 Rest of North America Filgrastim Market by Indication
    • 6.4.3 Rest of North America Filgrastim Market by Distribution Channel

Chapter 7. Company Profiles

  • 7.1 Abbott Laboratories
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental and Regional Analysis
    • 7.1.4 Research & Development Expense
  • 7.2 Amgen, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional Analysis
    • 7.2.4 Research & Development Expenses
  • 7.3 Pfizer, Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Regional Analysis
    • 7.3.4 Research & Development Expense
    • 7.3.5 Recent strategies and developments:
      • 7.3.5.1 Approvals and Trials:
  • 7.4 Novartis AG
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Segmental and Regional Analysis
    • 7.4.4 Research & Development Expense
    • 7.4.5 Recent strategies and developments:
      • 7.4.5.1 Product Launches and Product Expansions:
  • 7.5 Dr. Reddy's Laboratories Ltd.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental and Regional Analysis
    • 7.5.4 Research & Development Expense
    • 7.5.5 Recent strategies and developments:
      • 7.5.5.1 Partnerships, Collaborations, and Agreements:
      • 7.5.5.2 Product Launches and Product Expansions:
  • 7.6 Teva Pharmaceutical Industries Ltd.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Regional Analysis
    • 7.6.4 Research & Development Expenses
    • 7.6.5 Recent strategies and developments:
      • 7.6.5.1 Approvals and Trials:
  • 7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Regional Analysis
    • 7.7.4 Research & Development Expense
    • 7.7.5 Recent strategies and developments:
      • 7.7.5.1 Partnerships, Collaborations, and Agreements:
  • 7.8 Cadila Healthcare Ltd. (Zydus Cadila)
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Apotex, Inc.
    • 7.9.1 Company Overview
    • 7.9.2 Recent strategies and developments:
      • 7.9.2.1 Product Launches and Product Expansions:
  • 7.1 Toksoz Group
    • 7.10.1 Company Overview

LIST OF TABLES

  • TABLE 1 North America Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 2 North America Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 3 North America Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 4 North America Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 5 North America Biosimilar Market by Country, 2017 - 2020, USD Million
  • TABLE 6 North America Biosimilar Market by Country, 2021 - 2027, USD Million
  • TABLE 7 North America Biologic Market by Country, 2017 - 2020, USD Million
  • TABLE 8 North America Biologic Market by Country, 2021 - 2027, USD Million
  • TABLE 9 North America Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 10 North America Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 11 North America Chemotherapy induced Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 12 North America Chemotherapy induced Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 13 North America Chronic Neutropenia Market by Country, 2017 - 2020, USD Million
  • TABLE 14 North America Chronic Neutropenia Market by Country, 2021 - 2027, USD Million
  • TABLE 15 North America Other Indications Market by Country, 2017 - 2020, USD Million
  • TABLE 16 North America Other Indications Market by Country, 2021 - 2027, USD Million
  • TABLE 17 North America Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 18 North America Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 19 North America Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 20 North America Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 21 North America Retail Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 22 North America Retail Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 23 North America Online Pharmacies Market by Country, 2017 - 2020, USD Million
  • TABLE 24 North America Online Pharmacies Market by Country, 2021 - 2027, USD Million
  • TABLE 25 North America Filgrastim Market by Country, 2017 - 2020, USD Million
  • TABLE 26 North America Filgrastim Market by Country, 2021 - 2027, USD Million
  • TABLE 27 US Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 28 US Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 29 US Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 30 US Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 31 US Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 32 US Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 33 US Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 34 US Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 35 Canada Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 36 Canada Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 37 Canada Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 38 Canada Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 39 Canada Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 40 Canada Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 41 Canada Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 42 Canada Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 43 Mexico Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 44 Mexico Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 45 Mexico Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 46 Mexico Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 47 Mexico Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 48 Mexico Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 49 Mexico Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 50 Mexico Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 51 Rest of North America Filgrastim Market, 2017 - 2020, USD Million
  • TABLE 52 Rest of North America Filgrastim Market, 2021 - 2027, USD Million
  • TABLE 53 Rest of North America Filgrastim Market by Drug Type, 2017 - 2020, USD Million
  • TABLE 54 Rest of North America Filgrastim Market by Drug Type, 2021 - 2027, USD Million
  • TABLE 55 Rest of North America Filgrastim Market by Indication, 2017 - 2020, USD Million
  • TABLE 56 Rest of North America Filgrastim Market by Indication, 2021 - 2027, USD Million
  • TABLE 57 Rest of North America Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
  • TABLE 58 Rest of North America Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
  • TABLE 59 Key Information - Abbott Laboratories
  • TABLE 60 Key Information - Amgen, Inc.
  • TABLE 61 Key Information - Pfizer, Inc.
  • TABLE 62 Key Information - Novartis AG
  • TABLE 63 key information - Dr. Reddy's Laboratories Ltd.
  • TABLE 64 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 65 Key Information - Kyowa Kirin Co., Ltd.
  • TABLE 66 Key Information - Cadila Healthcare Ltd.
  • TABLE 67 Key Information - Apotex, Inc.
  • TABLE 68 Key Information - Toksoz Group

List of Figures

  • FIG 1 Methodology for the research